Local News

• Wyeth submits European marketing authorization application for its 13-Valent Vaccine  Wyeth Pharmaceuticals announced that it has submitted a marketing authorization application to the European Medicines Agency for approval to market its investigational 13-valent pneumococcal conjugate vaccine (PCV13) for infants and young children.
  Wyeth Pharmaceuticals December 03, 2008  
• Medtronic receives FDA approval of Sprint Quattro Secure S Single Coil Defibrillation Lead  Medtronic announced U.S. FDA approval of the Medtronic Sprint Quattro Secure® S single coil defibrillation lead (Model 6935) for use with implantable defibrillators in patients at risk for dangerous tachyarrhythmias (fast heartbeats) and sudden cardiac arrest.
  Medtronic, Inc. December 03, 2008  
• Forest Laboratories responds to unsolicited mini-tender offer  Forest Laboratories has been notified of an unsolicited mini-tender offer by TRC Capital Corporation of Toronto, Canada, a private investment company. Forest Laboratories has received a copy of the tender offer to purchase up to 3.0 million outstanding shares of the company's common stock.
  Forest Laboratories, Inc. December 03, 2008  
• EndoGastric Solutions launches EsophyX2 device  EndoGastric Solutions announced the launch of the EsophyX2 device. The next generation of its innovative EsophyX® device, EsophyX2 facilitates the creation of a robust, tight antireflux valve with the TIF2 advanced surgical procedure for the treatment of GERD.
  EndoGastric Solutions December 03, 2008  
• Cell Genesys and Takeda terminate collaboration agreement for GVAX Immunotherapy  Cell Genesys and Takeda Pharmaceutical have mutually agreed to suspend the further development of GVAX immunotherapy for prostate cancer and that Takeda has ended the collaboration agreement with Cell Genesys for the development and commercialization of the product.
  Cell Genesys, Inc. December 03, 2008  
• Quidel authorizes additional $25 million under stock repurchase program  Quidel announced that its Board of Directors has authorized an extension of the company's current stock repurchase program. The extension authorizes the repurchase of up to an additional $25 million in shares of Quidel common stock under the repurchase program.
  Quidel Corporation December 02, 2008  
• Questcor resubmits supplemental new drug application to FDA for H.P. Acthar(r) gel  Questcor Pharmaceuticals announced that it has resubmitted to the U.S. Food & Drug Administration (FDA) its supplemental New Drug Application (sNDA) seeking approval to market H.P. Acthar(r) Gel (repository corticotrophin injection) for the treatment of infantile spasms.
  Questcor Pharmaceuticals, Inc. December 02, 2008  
• Targeted Genetics realigns product development priorities  Targeted Genetics announced that it has realigned its product development priorities to focus on its ocular and neurological product candidates and its first use of expressed RNAi.
  Targeted Genetics Corporation December 02, 2008  
• Oxygen Biotherapeutics provides update on product development plans  Oxygen Biotherapeutics has posted an update on the company website that discusses the company's development plans for Oxycyte(R). Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.
  Oxygen Biotherapeutics, Inc. December 02, 2008  
• TorreyPines Therapeutics muscarinic agonist NGX267 meets primary endpoint in a Phase II  TorreyPines Therapeutics announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome.
  TorreyPines Therapeutics, Inc. December 02, 2008  

   (next 10 articles)